ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Philips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025

September 26, 2025

  • New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value
  • Philips debuts helium-free [2] BlueSeal RT 1.5T 70cm MR system with AI-powered SmartSpeed Precise, expanding its leadership in sustainable MR for radiation oncology

Amsterdam, the Netherlands – At the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will introduce groundbreaking additions in radiation oncology: the Philips Rembra RT and Philips Areta RT CT platforms, and the latest helium-free [2] BlueSeal RT 1.5T MR system. Designed to help radiation oncology teams deliver highly accurate, efficient, and patient-centered care, innovative technologies like the new NanoPanel Precise XD detector, built for AI and the AI-based Smartspeed Precise, represent a significant step forward in tackling the growing complexities of radiation therapy planning.


Setting new standards in CT simulation with speed, accuracy, and long-term value
CT imaging is the foundation of precision in radiation therapy planning, delivering accuracy to guide treatment. But as oncology teams face mounting demands for precision, efficiency, and consistency amid staffing and resource pressures, a new era of CT simulation is rising to meet the challenge.

Philips’ new Rembra RT and Areta RT systems are designed to make cancer treatment planning faster and more accurate.  These advanced scanners produce clearer, more consistent images so doctors can see tumors in greater detail and plan treatments with confidence. They also save valuable time with ultra-fast image reconstruction speeds up to 106 images per second, and easy-to-use touchscreen gantry controls that help 91% of care teams work more efficiently [3]. A wide 85 cm extended field of view and next-generation 4DCT imaging capabilities can capture a full respiratory cycle in one scan up to 500 scan seconds with breath rates of 4-40 breaths per minute.

Beyond imaging, the systems support remote collaboration for planning and training, helping care teams stay connected and efficient without adding extra staff. And with Philips’ industry-first Tube for Life Guarantee and a design for which 20 years of service could be provided (provided commercial upgrades and maintenance), hospitals gain reliable, long-term value while keeping costs lower. Patients also benefit directly, with a high-performance table that allows flexible positioning, faster workflows that shorten waiting times, and shared-use radiology capabilities on Rembra RT to maximize department efficiency.

“Philips invented CT Simulation and introduced the industry’s first Big Bore RT system,” said Dan Xu, Business Leader of CT at Philips. “With Rembra RT and Areta RT, we’re once again setting new standards in radiation therapy, empowering care teams with the precision, dependability, and speed they need to deliver the best outcomes for patients.”

Philips is also currently working with MVision AI to explore opportunities to include MVision AI’s Contour+ AI-powered auto-segmentation software with Philips CT simulators, including the new Rembra RT and Areta RT systems.  Contour+ delivers fast and precise automatic delineation of organs at risk and lymph node areas.

Philips expands MR leadership with helium-free BlueSeal RT [4]

Alongside its newest CT innovations, Philips is introducing BlueSeal MR RT in North America [5], the company’s latest helium-free [2] 1.5T 70cm MR system designed for radiation oncology. Powered by AI-based SmartSpeed Precise acceleration software, BlueSeal RT enables enhanced simulation confidence.

MR plays an increasingly vital role in radiation therapy, enabling clinicians to visualize tumors and surrounding healthy tissue with far greater detail, which is essential for planning precise treatments. By combining sustainability with advanced imaging, BlueSeal RT transforms therapy planning with enhanced simulation confidence, reducing registration errors to help protect healthy organs. In addition, MR-only imaging with MRCAT simplifies workflows. With full MR-only simulation protocols in as little as 10 minutes, patients also benefit, experiencing shorter scans that improve comfort and overall experience, especially for those wearing a mask.

With approximately 2,000 helium-free [2] MR scanners installed worldwide, Philips is driving the shift to sustainable MR. BlueSeal RT extends this leadership into radiotherapy by addressing a key challenge for oncology departments: installing MR systems in complex clinical environments such as Radiation Oncology departments. Its light-weight, vent-pipe-free design opens new siting possibilities - whether in basements, bunkers, or higher floors - while also lowering cost and energy use through helium-free [2] operation and PowerSave+ efficiency.

“BlueSeal RT is leading the way in MR for radiotherapy,” said Ioannis Panagiotelis, PhD, Business Leader MR at Philips. “By combining helium-free [2] sustainability with AI-powered acceleration, we’re enabling radiation oncology teams to plan and simulate with greater speed, accuracy, and confidence—while enhancing the patient experience.”

“Radiation oncology teams need transformative innovation to meet today’s accuracy, workflow, and cost challenges,” said Christopher M. Freese, MD, The Christ Hospital. “With Rembra RT, Areta RT, and BlueSeal RT, Philips is setting new standards for precision and efficiency in radiation therapy across CT and MR.” 

For more information, visit Philips at ASTRO 2025.

[1] 510(k) pending. Not available for sale in the US.
[2] 7 liters of helium are permanently enclosed in the cryogenic circuit.
[3] Based on a third-party survey of 145 users across eight countries. Quantitative Report 2020 Incisive CT. The MarketTech Group. November, 2020. Actual results in other cases may vary.
[4] BlueSeal RT is a configuration of BlueSeal XE/SE.
[5] BlueSeal RT is an add-on to the existing Ingenia 1.5T and 3.0T MR systems that makes the system suitable for MR imaging for radiation therapy planning purposes. BlueSeal RT consists of RTGo SW and MR CouchTop accessory. RTgo is a software that provides MR-RT functionality including MRCAT (MRCAT Prostate, MRCAT Pelvis, MRCAT Brain, MRCAT Head &Neck)

For further information, please contact:

Kathy O’Reilly
Philips Global External Relations
Tel.: +1 978-221-8919
E-mail: kathy.oreilly@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.97
+2.76 (1.23%)
AAPL  268.81
+5.99 (2.28%)
AMD  259.67
+6.75 (2.67%)
BAC  53.02
+0.45 (0.86%)
GOOG  269.93
+9.42 (3.62%)
META  750.82
+12.46 (1.69%)
MSFT  531.52
+7.91 (1.51%)
NVDA  191.49
+5.23 (2.81%)
ORCL  281.40
-1.93 (-0.68%)
TSLA  452.42
+18.70 (4.31%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.